|
ACTELION PHARMACEUTICALS, a Janssen Pharmaceutical Company of Johnson and Johnson, GRANT PORTAL
Pulmonary Hypertension:
Pulmonary Hypertension focuses on the discovery, development and commercialization of innovative treatments to serve critical, unmet medical needs. We strive on delivering ground-breaking medicines that improve patients' lives. We offer funding and support because we believe organizations are an important support network and source for raising awareness and providing education.
|
AS OF FRIDAY MAY 14TH, THIS SITE WAS CLOSED WITH NO ACCESS. ACTELION/JANSSEN PH WILL BE LAUNCHING A NEW GRANTS SITE ON JUNE 17TH LOCATED here. Please contact Rocket Romer at rromer2@its.jnj.com with any questions.
No live programming will be supported at this time. Virtual programs ONLY. Live programming will be considered once the pandemic restrictions have been lifted in full.
Please click here to complete a Janssen required Certificate of Separation. This document must be completed, signed, and uploaded to your organization profile to complete the CME review process.
.
Charitable Contribution applications can be requested by clicking here here. Thank you.
To request Sponsorship support for an event, please contact Dana Roman at droman10@its.jnj.com. Thank you.
Areas Of Interest:
What are Pulmonary Hypertension US Educational Objectives?
- Increase awareness of Pulmonary Arterial Hypertension (PAH) and associated diseases.
- Increase awareness of the need for early recognition, diagnosis, and treatment of PAH.
- Expand knowledge basis for the appropriate use of currently available PAH therapies.
- Explore emerging science as it relates to improved diagnosis and treatment of PAH.
What therapeutic areas will be considered by Pulmonary Hypertension?
| | 